Clicky

PharmAust Ltd(ECQ)

Description: PharmAust Limited develops targeted cancer therapeutics for humans and animals in Switzerland, Australia, Sweden, the United States, and internationally. The company develops drug discovery intellectual property for the treatment of various cancers, and neurological diseases. Its lead candidate is Monepantel (MPL), a small molecule drug which is in Phase II clinical trials for the treatment of cancer. The company also provides products and services in synthetic and medicinal chemistry to the drug discovery and pharmaceutical industries worldwide. The company has a research agreement with the Walter and Eliza Hall Institute to investigate the effects of MPL upon human T-lymphotrophic virus-1 (HTLV-1) infections in vitro. It serves drug discovery and pharmaceutical industries. PharmAust Limited was incorporated in 2000 and is based in Bentley, Australia.


Keywords: Cancer Medication Pharmacy Health Sciences Pharmacology Drug Discovery Treatment Of Cancer Infection Pharmaceutical Sciences Pharmaceutical Industries Medicinal Chemistry Virus Cancer Therapeutics Treatment Of Various Cancers Neurological Diseases

Home Page: www.pharmaust.com

5/3 Brodie Hall Drive
Bentley, WA 6102
Australia
Phone: 61 8 9202 6814


Officers

Name Title
Dr. Roger Aston B.Sc., BSc (Hons), Ph.D. Exec. Chairman & Acting CEO
Mr. Sam Michael Wright A.C.I.S., ACIS, AFin, DipAcc, M.A.I.C.D., MAICD Fin. Director, Company Sec. & Non-Exec. Director
Mr. Robert Charles Bishop LLB (Hons) Exec. Director
Ms. Fiona Milner Gen. Mang. of Epichem Pty Ltd
Dr. Gary Pitt Head of Chemistry
Dr. James Rixson Head of Production

Exchange: F

Country: DE

Currency: Euro (€)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 2.3603
Price-to-Sales TTM: 2.8566
IPO Date:
Fiscal Year End: June
Full Time Employees: 0
Back to stocks